论文部分内容阅读
非森(Fisons)公司新的抗过敏药色甘酸钠口服制剂,在美国已得到批准上市,用于着色性荨麻疹患者。着色性荨麻疹患者在美约有4000人。它是令人苦恼的衰弱性疾病,症状包括荨麻疹、骨痛、慢性疲劳和腹泻,是由热或情绪经常受抑而引起的疾病。该病特点是肥大细胞组织增生。而本品有稳定肥大细胞膜和抑制组胺及白细胞素的释放作用。据Fisons报道,临床证明有预防作用。本品按配方制成溶于水的白色粉末,每粒胶囊中含该药100mg.通常首次剂量成人2粒,每天4次。
Fisons’ new anti-allergic drug, cromolyn oral, has been approved for sale in the United States for patients with urticaria. Coloring urticaria patients in the United States about 4000 people. It is a distressing debilitating condition and symptoms include urticaria, bone pain, chronic fatigue and diarrhea, a disease caused by the constant suppression of heat or emotions. The disease is characterized by mast cell proliferation. This product has a stable mast cell membrane and inhibit the release of histamine and leukocyte release. According to Fisons reports, clinical evidence of prophylaxis. This product is made according to the formula made of water-soluble white powder, each capsule contains the drug 100mg. Usually the first dose of 2 adults, 4 times a day.